Can risk-sharing and real-world evidence can provide traction in treating the brain cancer Glioblastoma?
Novocure’s Optune will be tested alongside investigational Celgene drug marizomib.
Watson for Genomics produces treatment insights for glioblastoma in 10 minutes.
Median overall survival improved from 15 months to 21 months when combined with chemotherapy.
Does artificial intelligence hold the key to cancer drug R&D?
Drug will be tested as a monotherapy for glioblastoma multiforme.
Novocure’s Optune device shown to be safe and tolerable in recurrent ovarian cancer.
